ASND Form 144 Files Proposed Sale of 25,000 ADS via Merrill Lynch

Rhea-AI Filing Summary

Form 144 notice for Ascendis Pharma A/S (ASND): The filer proposes to sell 25,000 American Depositary Shares on 08/14/2025 through Merrill Lynch on NASDAQ. The aggregate market value of the proposed sale is $4,789,998.27. The shares were acquired the same day on 08/14/2025 by warrant exercise from Ascendis Pharma A/S and paid in cash. The filing reports 60,454,589 shares outstanding and indicates no securities sold in the past three months by the account. The notice includes the seller's certification that no undisclosed material adverse information is known.

Insights

Securities Analyst

TL;DR: Routine insider sale notice: 25,000 ADSs from warrant exercise, executed through Merrill Lynch, not previously sold in the last three months.

This Form 144 documents a proposed sale of 25,000 American Depositary Shares valued at about $4.79 million, acquired via warrant exercise and paid in cash on the same date. The filing is procedural, notifying the market of an intended resale under Rule 144. With 60.45 million shares outstanding, the proposed sale represents a small fraction of total shares and appears non-material to capitalization. The absence of prior sales in the past three months and the seller's certification about material information are standard disclosures.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure; signature certification and trading channel details meet Rule 144 notice requirements.

The notice provides required information: broker identity (Merrill Lynch), transaction date, acquisition method (warrant exercise), and consideration (cash). The inclusion of the seller's representation about lack of undisclosed material information aligns with regulatory expectations. No related-party aggregation or recent sales are reported, simplifying compliance review. This filing should be viewed as administrative rather than indicating governance or operational issues at the issuer.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	25000	4789998.27	60454589	08/14/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares	08/14/2025	Warrant Exercise	Ascendis Pharma A/S			25000	08/14/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Ascendis Pharma (ASND) disclose?

The filing discloses a proposed sale of 25,000 ADS valued at $4,789,998.27 to be sold on 08/14/2025 through Merrill Lynch on NASDAQ.

How were the 25,000 shares acquired according to the filing?

The shares were acquired on 08/14/2025 by warrant exercise from Ascendis Pharma A/S and paid for in cash.

Does the Form 144 report recent sales by the same person?

No. The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

How many shares outstanding does the filing show?

The filing lists 60,454,589 shares outstanding for the issuer.

Who is the broker handling the proposed sale?

The broker named in the filing is Merrill Lynch, address listed as 225 Liberty St Floor 37, New York, NY 10281.